GO
Loading...

Enter multiple symbols separated by commas

Pharmaceuticals

More

  • FDA to make ruling on new cholesterol drugs Tuesday, 9 Jun 2015 | 4:16 PM ET
    FDA to make ruling on new cholesterol drugs

    Discussing the FDA panel on a new highly anticipated cholesterol drug, with Phil Nadeau, Cowen & Co. analyst

  • FDA panel backs cholesterol drug Tuesday, 9 Jun 2015 | 4:16 PM ET
    FDA panel backs cholesterol drug

    CNBC's Meg Tirrell reports on a key ruling by and FDA panel on a new cholesterol drug.

  • 10 drugs to hit fed budget by $50B over decade Tuesday, 9 Jun 2015 | 1:42 PM ET
    Health Care

    Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.

  • SHANGHAI, June 9- A British corporate investigator linked to a bribery scandal in China involving drugmaker GlaxoSmithKline PLC is to be released early from a 2 1/ 2- year sentence in a Chinese jail, a source close to his family said on Tuesday. The case was intertwined with an investigation of GSK in China which rocked the country's pharmaceutical market and led...

  • The Swiss drugmaker, which has licensed rights to dalcetrapib to Quebec- based DalCor Pharmaceuticals, said on Tuesday it would provide a companion diagnostic for use in the Phase III study. DalCor estimates about $250 million will be needed for the project, which will be run in collaboration with the Montreal Heart Institute and will screen more than 30,000...

  • FDA targets 'bad' cholesterol drug Tuesday, 9 Jun 2015 | 6:31 AM ET
    FDA targets 'bad' cholesterol drug

    CNBC's Meg Tirrell reports the FDA meets today and tomorrow to discuss and vote on recommendation for approval of new cholesterol drugs, Praluent and Repatha.

  • Extreme form of tuberculosis enters US Tuesday, 9 Jun 2015 | 6:27 AM ET
    Extreme form of TB enters US

    A woman carrying an extreme form of tuberculosis enters the country, traveling to at least three states before seeking medical treatment, reports CNBC's Meg Tirrell.

  • AMSTERDAM, June 8- Executives at Israeli drugmaker Teva sent an open letter to takeover target Mylan on Monday, saying they remain committed to a deal and reiterated that Teva's $40 billion takeover proposal would benefit shareholders of both firms. In the letter, addressed to Mylan executive founder Robert Coury, Teva CEO Erez Vigodman and Chairman Yitzhak...

  • This sector is set for more M&A Monday, 8 Jun 2015 | 1:00 AM ET
    This sector is set for more M&A

    John Studzinski, vice chairman of Blackstone Group, tells CNBC that the healthcare sector is set for more consolidation.

  • *Deal gives Cardinal Health more generic volume. June 5- Cardinal Health Inc said it would buy privately held drug distributor Harvard Drug Group for $1.12 billion to boost volumes of its generic distribution business. The Livonia, Michigan- based Harvard Drug Group, a distributor of generic and over-the-counter drugs, had revenue of about $450 million in 2014,...

  • June 5- Orexigen Therapeutics Inc and partner Takeda Pharmaceutical Co Ltd said they had filed a lawsuit against Actavis Plc to block a generic version of diet-pill Contrave. The lawsuit, filed at a Delaware district court, alleges that Actavis has infringed patents on Orexigen and Takeda's weight-loss treatment. Actavis and Teva Pharmaceutical Industries...

  • FDA panel approves 'female Viagra' drug Friday, 5 Jun 2015 | 7:55 AM ET
    FDA panel approves 'female Viagra' drug

    CNBC's Meg Tirrell reports on the woman's libido drug.

  • June 5- Cardinal Health Inc said it would buy privately held drug distributor Harvard Drug Group for $1.12 billion to expand its customer base and bolster its generics business. The Harvard Drug Group is a distributor of generic and over-the-counter drugs. The Harvard Drug Group had revenues of about $450 million in 2014, Cardinal health said in a statement.

  • A new pink cousin for the little blue pill Friday, 5 Jun 2015 | 7:00 AM ET
    A new pink cousin for the little blue pill

    An FDA panel votes to approve a pill to improve female libido.

  • Medivation: Importance of drug innovation Friday, 5 Jun 2015 | 5:15 AM ET
    Medivation: Importance of drug innovation

    David Hung, CEO of Medivation, explains how their prostate cancer drug, Xtandi, turned their company around.

  • FDA panel backs female 'Viagra' Thursday, 4 Jun 2015 | 4:26 PM ET
    FDA panel backs female 'Viagra'

    CNBC's Meg Tirrell reports on the backing of a female libido drug. The FDA panel says risk management must go beyond labeling.

  • 2015's pharma buzzword? Immuno-oncology Thursday, 4 Jun 2015 | 5:50 AM ET
    2015's pharma buzzword? Immuno-oncology

    Vamil Divan, senior analyst at Credit Suisse, explains why Bristol-Myers could benefit the most from the immune-oncology trend that's emerging in pharmaceuticals.

  • The USDA has been developing a vaccine against bird flu and was weighing whether to release it to drug makers for widespread production. Turkey producers in Minnesota, where nearly 9 million birds have been affected by the disease since the beginning of the year, had asked the USDA to approve use of a vaccine to help prevent further infections.

  • Teva raises stake in Mylan Wednesday, 3 Jun 2015 | 9:15 AM ET
    Teva raises stake in Mylan

    Teva is poised to raise its stake in Mylan as it pursues its takeover bid. - Reuters

  • Teva poised to raise its stake in Mylan: Report Wednesday, 3 Jun 2015 | 7:07 AM ET
    Mylan headquarters Canonsburg, Pennsylvania

    Teva Pharmaceutical is looking to buy more shares in Mylan, positioning itself for a possible legal challenge to the generics drugmaker.